Volume 28, Number 12—December 2022
Research Letter
Omicron BA.5 Neutralization among Vaccine-Boosted Persons with Prior Omicron BA.1/BA.2 Infections
Rune M. Pedersen, Line L. Bang, Ditte S. Tornby, Lone W. Madsen, Dorte K. Holm, Thomas V. Sydenham, Isik S. Johansen, Thøger G. Jensen, Ulrik S. Justesen, and Thomas E. Andersen
Table
Characteristics of persons with and without Omicron BA.1/BA.2 breakthrough infection who received COVID-19 vaccines and booster doses, Denmark*
| Characteristics | Vaccines and booster | Vaccines, booster, and Omicron breakthrough |
|---|---|---|
| Total no. persons |
24 |
12 |
| Sex, no. (%) | ||
| F | 17 (70.8) | 8 (66.6) |
| M |
7 (29.2) |
4 (33.4) |
| Median age, y (IQR) |
41 (32–51) |
47 (40–50) |
| Median no. days (IQR) between vaccination, infection, and sampling | ||
| Between first and second dose | 29 (27–36) | 28 (26–34) |
| Between second and third dose | 152 (42–199) | 200 (159–228) |
| Between third dose and sampling | 29 (23–34) | 90 (77–143) |
| Between third dose and infection | NA | 55 (31–109) |
| Between infection and sampling | NA | 33 (24–38) |
*Participants received 3 doses of BNT162b2 (Pfizer-BioNTech, https://www.pfizer.com), 2 initial vaccines and a booster dose. IQR, interquartile range; NA, not applicable
Page created: October 17, 2022
Page updated: November 21, 2022
Page reviewed: November 21, 2022
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.